Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges
Lung Cancer: Targets and Therapy · 2026-05 · Volume 17 · 1-8
DOI: 10.2147/lctt.s592922 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung Cancer: Targets and Therapy, 2026-05. Verfasst von Kim Abbegail Tan Aldecoa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.
- Chao Family Comprehensive Cancer Center, Orange, CA, USA.
ORCID-Profile: Zhaohui Liao Arter, Misako Nagasaka
Zitieren
APA
Aldecoa, K. A. T., Arter, Z. L., Ou, S. I., & Nagasaka, M. (2026). Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges. Lung Cancer: Targets and Therapy, Volume 17, 1-8. https://doi.org/10.2147/lctt.s592922
Vancouver
Aldecoa KAT, Arter ZL, Ou SI, Nagasaka M. Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges. Lung Cancer: Targets and Therapy. 2026;Volume 17:1-8. doi:10.2147/lctt.s592922
BibTeX
@article{Aldecoa2026,
author = {Aldecoa, Kim Abbegail Tan and Arter, Zhaohui Liao and Ou, Sai-Hong Ignatius and Nagasaka, Misako},
title = {Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges},
journal = {Lung Cancer: Targets and Therapy},
year = {2026},
volume = {Volume 17},
pages = {1--8},
doi = {10.2147/lctt.s592922}
}
EUVIMED